Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) Director Christy Jones sold 6,430 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total transaction of $147,890.00. Following the transaction, the director owned 19,564 shares of the company’s stock, valued at approximately $449,972. This trade represents a 24.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beta Bionics Stock Performance
BBNX stock traded down $0.62 on Wednesday, hitting $22.19. 1,396,325 shares of the company’s stock were exchanged, compared to its average volume of 1,192,758. The firm has a 50 day moving average price of $17.88 and a two-hundred day moving average price of $14.21. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The stock has a market cap of $998.33 million, a P/E ratio of -13.45 and a beta of 3.37.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Sell-side analysts expect that Beta Bionics, Inc. will post -2.06 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Report on Beta Bionics
Beta Bionics News Summary
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Beta Bionics announced an agreement with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening Beta Bionics’ competitive position in automated insulin delivery. Beta Bionics Announces Agreement to Integrate the iLet and mint with Senseonics’ Eversense 365
- Neutral Sentiment: Multiple law firms are soliciting investors to serve as lead plaintiff in the same federal securities class action. The deadline is November 3, 2026, for investors who purchased BBNX shares between July 30, 2025 and February 24, 2026. The repeated notices do not represent separate judgments against the company, but they are likely to maintain attention on the dispute. Johnson Fistel BBNX Investor Alert
- Negative Sentiment: The lawsuit alleges that Beta Bionics failed to timely disclose a June 2025 FDA Form 483 and more than 18,000 complaints related to its iLet device, and that subsequent disclosures caused sharp declines in BBNX shares. These are allegations, not established findings, but the case creates litigation costs, reputational risk and uncertainty around regulatory compliance and product demand. Levi & Korsinsky BBNX Securities Class Action Notice
- Negative Sentiment: Additional caution comes from reported insider activity: executives recorded 24 open-market sales and no purchases during the past six months. With BBNX trading well above its 200-day average and analysts’ reported median price target of $18, investors may be especially sensitive to legal and execution risks.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Eventide Asset Management LLC boosted its stake in shares of Beta Bionics by 0.8% during the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after acquiring an additional 37,476 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Beta Bionics in the 2nd quarter valued at about $52,340,000. Eversept Partners LP raised its holdings in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Beta Bionics in the 4th quarter worth about $40,437,000. Finally, Perceptive Advisors LLC boosted its position in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares in the last quarter.
About Beta Bionics
Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.
The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.
Featured Articles
- Five stocks we like better than Beta Bionics
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
